Roivant Sciences (ROIV) Liabilities from Discontinued Operations (2024)
Roivant Sciences' (ROIV) quarterly Liabilities from Discontinued Operations came in at 401213000.0 in Q3 2024, up 263.4% on a QoQ basis from 110405000.0 in Q1 2024.
Powered by 
Analysis
Roivant Sciences (ROIV) Liabilities from Discontinued Operations (2024) Analysis & Trends
Roivant Sciences (ROIV) has 1 years of Liabilities from Discontinued Operations data on file, last reported at 401213000.0 in Q3 2024.
- Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 401213000.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was 401213000.0 (changed N/A YoY) and the FY2024 annual result came in at 110405000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations advanced to 401213000.0 in Q3 2024, from 110405000.0 in the prior quarter.
- In the past five years, Liabilities from Discontinued Operations ranged from a high of 401213000.0 in Q3 2024 to a low of 110405000.0 in Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 25.21 Bn | 25.21 Bn | 1.16 Mn |